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709Abstracts
ition. The follow-up was done in databases Pharmaca Fennica
(1994–2003), SLD Pharma (1993–2002), SLD Nordic
(1998–2003) and SLD Price (1997–2003). Nominal and ofﬁcial
Consumer Price Index (Statistics Finland) adjusted (real) retail
prices (RP; including 8% VAT) were used. RESULTS: From 1993
to 2003, we identiﬁed 111 marketing companies, 1196 active
substances, 2515 trade names (products) and 9606 packages. In
1994 altogether 19 marketers introduced 32 NCE’s, of which
13% (4/32) were combination products. Some 87% (28/32) of
NCE’s, and 70% (42/60) of packages survived till the end of the
follow-up period. From 1994 to 2003 mean package RP
decreased 19% in nominal and 30% in real prices. Real prices
decreased 32% in No Refund, 31% in Basic (50%), 19% in
Lower (75%) Special and 22% in Higher (100%) Special Refund
categories. CONCLUSIONS: In 1994 Finland became a member
of the European Economic Area. Since then, retail prices have
decreased markedly in Finland even before the introduction of
generic and parallel import substitution. The observed 30%
decrease in real retail prices among the survival cohort suggests
that medicines have clearly become more cost-effective.
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OBJECTIVES: Anticoagulants are widely used and represent a
class of drugs that are problem-prone and have a high potential
for adverse patient outcomes. As such, these drugs may be
amenable to the use of prescribing guidelines. However, rela-
tively little has been published on the effect of such guidelines
on clinical outcomes or costs of care. The purpose of this study
was to assess whether guidelines improve the appropriateness of
prescribing, clinical outcomes, and the costs associated with use
of anticoagulants in a sample of community hospitals in the
United States. METHODS: A retrospective analysis was per-
formed of data voluntarily collected by 15 hospitals before
(July–September 2001) and after (March–May 2002) implemen-
tation of anticoagulant prescribing guidelines. Statistical 
analyses of both patient-level and hospital-level variables were
conducted. RESULTS: Implementation of the guidelines resulted
in a signiﬁcant increase in the proportion of anticoagulants that
were prescribed appropriately (59.8% v. 86.9%, p < 0.001). The
guidelines also resulted in a shift in the type of anticoagulants
prescribed (decreased use of unfractionated heparin and
increased use of low-molecular-weight heparins). There was sug-
gestive evidence, though not statistically signiﬁcant, that the
guidelines resulted in fewer anticoagulant-associated adverse
events (total bleeding RR = 0.71) and lower costs (savings of
$56.15 per patient per day). CONCLUSIONS: While limitations
existed with the study design, sufﬁcient beneﬁts were identiﬁed
to warrant hospitals to consider use of these or similar guide-
lines on a routine basis. Clearly, additional study in this area
would be useful.
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Methadone maintenance programs (MMP) are used to treat
opioid addiction. In Spain, there are currently no practice guide-
lines available in MMP. OBJECTIVES: The present study reports
the use of a Delphi process to develop consensus regarding spe-
ciﬁc recommendations to include in MMP guidelines for use in
Catalonia, Spain. METHODS: The ﬁrst draft of the guidelines
were reviewed to determine where recommendations might be
needed but for which evidence was lacking in the literature, and
to generate potential items for inclusion in the Delphi question-
naire. Potential items were revised by guideline authors to agree
on ﬁnal inclusion and wording. These were included in a ques-
tionnaire administered in a three round Delphi process to
develop consensus on their inclusion in the guidelines as recom-
mendations. Panelists (n = 26) were a multidisciplinary group,
and all experts in MMP. A 4-point response option was used,
and when consensus was reached on a given item it was omitted
from the following Delphi rounds. All responses were anony-
mous and questionnaire administration was by e-mail and fax.
RESULTS: The questionnaire administered in the ﬁrst round of
the Delphi process consisted of 32 items formulated as recom-
mendations and grouped into four sections: “Entry, follow-up
and ﬁnalization of MMP” (16 items) “Take home” (5 items),
methadone in pregnancy (3 items), and “other aspects” (8 items).
In the ﬁrst round, consensus was reached on 17 of the 32 items;
in the second round, on 7 items and in the third round on 4
items. In total, consensus was reached for 28 of the 32 potential
recommendations initially included. A total of 23 recommenda-
tions deriving from the Delphi process were included in the
guidelines. CONCLUSIONS: The Delphi technique was useful
in obtaining expert consensus on recommendations to be
included in these guidelines, when evidence supporting recom-
mendations was not available in the literature.
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OBJECTIVES: To model the perspective of the generic drug
market in France over the 2004–2008 period, given the rapidly
increasing generic substitution rate and arrival on that market of
a large number of best-selling drugs. METHODS: We simulated
the development of the drug market under two sets of hypothe-
sis. In the ﬁrst hypothesis, we considered only the 129 molecules
which are presently available on the generic market and we froze
the substitution rate at the level reached in 2003. In the second
hypothesis we considered the 56 additional molecules, the patent
of which will expire between 2004 and 2008 and we extrapo-
lated the increase of the substitution rate observed over the last
years. We used Box-Jenkins technique to model the market evo-
lution. We made the assumption that generic ex-factory price will
be 40% below the princeps price. We ﬁnally computed the yearly
and aggregated difference between the two scenarios, from a
global market perspective and from the Health Insurance per-
spective taking into account the reimbursement rate of each 
compound. RESULTS: Over the considered period, the patent of
some of the best-selling drugs such as omeprazole, pravastatine,
simvastatine, etc. will expire. All together these drugs represent
15% of the 2003 reimbursed drug market. The substitution rate
will reach 80%, 4 years after patent expiration. This will result
in saving Health Insurance an estimated 1 billion Euro per year
as soon as 2006. The aggregated savings on the full period will
be above ﬁve billion Euros. Two-thirds of the savings will be
attributable to the new generic drugs. CONCLUSIONS: The
